Nurix Therapeutics, Inc. Cash Flow Statement
NRIX / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Nurix Therapeutics, Inc. used $249M in operating cash flow and negative free cash flow of $263M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$264.5M | -$193.6M | -$143.9M | -$117.2M | -$21.7M | -$43.2M | -$21.7M |
| Depreciation & Amortization | $8.7M | $9.3M | $7.5M | $2.8M | $2.4M | $2.2M | $2.4M |
| Operating Cash Flow | -$249.5M | -$172.6M | -$81.4M | -$84.4M | $601.0K | -$80.0K | $601.0K |
| Capital Expenditures | $14.0M | $9.3M | $8.4M | $5.7M | $1.7M | $4.6M | $1.7M |
| Free Cash Flow | -$263.5M | -$181.9M | -$89.8M | -$90.0M | -$1.1M | -$4.6M | -$1.1M |
| FCF Margin | -313.7% | -333.4% | -116.6% | -302.6% | -3.4% | -26.0% | -3.4% |